Clinical Trial Update: A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RC48-ADC targeting HER2-expressing metastatic breast cancer with PAM pathway activation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN